About Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a company based in Cambridge (United States) founded in 2015 was acquired by Regeneron Pharmaceuticals in April 2022. Checkmate Pharmaceuticals has raised $175.08 million across 6 funding rounds from investors including Regeneron Pharmaceuticals, BrightEdge and Longitude Capital. The company has 16 employees as of December 31, 2018. Checkmate Pharmaceuticals operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 16 as on 31 Dec, 2018
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Checkmate Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$175.08 M (USD)
in 6 rounds
-
Latest Funding Round
$85.08 M (USD), Series C
Jun 18, 2020
-
Investors
Regeneron Pharmaceuticals
& 10 more
-
Employee Count
16
as on Dec 31, 2018
-
Acquired by
Regeneron Pharmaceuticals
(Apr 19, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Checkmate Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
229 people
Software Development Team
223 people
Senior Team
81 people
Product Management Team
55 people
Legal and Compliance
46 people
Operations Team
43 people
Data Analysis and Operations Team
37 people
Human Resources and Administration
29 people
Unlock access to complete
Funding Insights of Checkmate Pharmaceuticals
Checkmate Pharmaceuticals has successfully raised a total of $175.08M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $85.08 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Checkmate Pharmaceuticals
Checkmate Pharmaceuticals has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, BrightEdge and Longitude Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Locked | Locked | Locked |
Investor details for Checkmate Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Checkmate Pharmaceuticals
Investment portfolio details for Checkmate Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Checkmate Pharmaceuticals
Detailed financials for Checkmate Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Checkmate Pharmaceuticals Comparisons
Peer comparison for Checkmate Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Checkmate Pharmaceuticals
Checkmate Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Checkmate Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Checkmate Pharmaceuticals
Complete news archive for Checkmate Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Checkmate Pharmaceuticals
Checkmate Pharmaceuticals was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Checkmate Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Checkmate Pharmaceuticals is a funded company, having raised a total of $175.08M across 6 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Checkmate Pharmaceuticals is 16.
Founded in 2015 and based in Cambridge, United States, Checkmate Pharmaceuticals operates in the biotechnology sector. Focus is placed on research and development of CpG DNA-based therapies to stimulate the innate immune system against tumors. This approach integrates Toll-like receptor 9 activation with checkpoint inhibitors. The lead candidate, CMP-001, a CpG-A oligonucleotide, is evaluated in combination with pembrolizumab for melanoma treatment in a Phase 1b trial.
Checkmate Pharmaceuticals's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Checkmate Pharmaceuticals has 11 investors. Key investors include Regeneron Pharmaceuticals, BrightEdge, Longitude Capital, Novo Holdings, and Medicxi.